BiovaxID (dasiprotimut-T) / National Cancer Institute, Accentia - LARVOL DELTA

Fast Tracking-Vaccine Safety, Efficacy, and Lessons Learned: A Narrative Review. (PubMed, Vaccines (Basel)) - "Five articles about BiovaxID, THERATOPE, Sipuleucel-T, and AIDSVAX were also reviewed. The previous fast-tracked vaccines were safe and efficacious. The lessons drawn from previous studies highlighted the significance of planning and utilizing global resources during significant outbreaks."

Journal • Review • Infectious Disease • Narcolepsy • Novel Coronavirus Disease • Sleep Disorder

Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma (clinicaltrials.gov) - P2; N=26; Completed; Sponsor: National Cancer Institute (NCI); Trial completion date: Jun 2022 ➔ Jun 2021; Active, not recruiting ➔ Completed

Clinical • Trial completion • Trial completion date • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Oncology • CTCs

Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma (clinicaltrials.gov) - P2; N=26; Active, not recruiting; Sponsor: National Cancer Institute (NCI); Trial completion date: Jun 2021 ➔ Jun 2022

Trial completion date • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Oncology • CTCs

Biovest to seek marketing approval in the EU for BiovaxID personalized lymphoma cancer vaccine (Biovest) - Biovest plans to file for MAA with EMA for BiovaxID, for the treatment of follicular NHL; Under the EMA centralized procedure, Biovest will simultaneously seek approval for BiovaxID for all EU-member countries; Biovest could receive a decision regarding EU marketing approval for BiovaxID within 12 months after the MAA submission

Anticipated MAA submission • Hematological Malignancies • Non-Hodgkin’s Lymphoma